Eli Lilly and CompanyLLYNYSE
Loading
Price to Sales: Premium ValuationElevated
Percentile Rank86
3Y CAGR+6.7%
5Y CAGR+17.6%
Year-over-Year Change
Price-to-sales ratio
3Y CAGR
+6.7%/yr
vs +21.8%/yr prior
5Y CAGR
+17.6%/yr
Recent deceleration
Acceleration
-15.1pp
Decelerating
Percentile
P86
Within normal range
vs 5Y Ago
2.2x
Strong expansion
Streak
1 yr
Consecutive declineElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 14.81 | -4.1% |
| 2024 | 15.44 | +0.5% |
| 2023 | 15.36 | +26.1% |
| 2022 | 12.18 | +30.9% |
| 2021 | 9.30 | +41.3% |
| 2020 | 6.58 | +16.7% |
| 2019 | 5.64 | +1.9% |
| 2018 | 5.53 | +24.4% |
| 2017 | 4.45 | +16.6% |
| 2016 | 3.82 | - |